Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desipramine in Infantile Neuroaxonal Dystrophy
NCT03726996Phase 4Terminated
- Sponsor
- Duke University
- Start
- Jan 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of desipramine in infantile neuroaxonal dystrophy (INAD), sponsored by Duke University. Primary endpoints: Gross Motor Function Measure at 12 months, Quick Motor Function Test at 12 months and 1 more. Started Jan 2019; status: terminated.
02
Drugs
desipramine
03
Conditions
infantile neuroaxonal dystrophy (INAD)
Beyond the preview
Go deeper on NCT03726996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726996.